ADG206

Phase 1Active
0 watching 0 views this week๐Ÿ’ค Quiet
25
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced/Metastatic Solid Tumors

Conditions

Advanced/Metastatic Solid Tumors

Trial Timeline

Feb 13, 2023 โ†’ Aug 30, 2026

About ADG206

ADG206 is a phase 1 stage product being developed by Adagene for Advanced/Metastatic Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT05614258. Target conditions include Advanced/Metastatic Solid Tumors.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05614258Phase 1Active